Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Business Wire•12/11/2026•08:00 ET
0
Key Highlights
- ➤Merck KGaA agreed to acquire Silence Therapeutics; transaction expected to close in Q1 2027.
- ➤Cash and equivalents reached $247.7 million, including $201.3 million from an upsized offering.
- ➤Q3 net loss narrowed to $12.4 million, or $0.08 per share, from $21.0 million.
- ➤SANRECO Phase 2 topline results supported once-every-three-month dosing for investigational divesiran.
- ➤Q3 R&D expenses fell to $9.3 million from $20.5 million year over year.
Silence Therapeutics Highlights Recent Business Achievements and Reports Third Quarter 2026 Financial Results
Silence Therapeutics plc, (Nasdaq: SLN), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for the third quarter ended September 30, 2026, and provided an update on other recent business achievements.
Get started
Create a free account to read the full story.